Korea Health Industry Development Institute President Soon-Do Cha talks to Scrip how the government agency’s support strategy to the domestic biopharma industry may be changing in line with the industry’s increased globalization move and how he views the country’s policy stance should improve going forward to meet its goal of becoming a strong biohealth nation.

As the global economy remains in a slump, even big pharmas such as Novartis and Pfizer are cutting costs. So how should Korean biopharmas adapt to such an environment and move ahead? Korea Drug Development Fund CEO H. Samuel Muk provides some ideas on how domestic players can survive in this new global reality.

The Pink Sheet’s roundup of key regulatory issues in Korea for 2022 and outlook for this year.

Scrip takes a look at key recent drug development activities in the NASH area by Korean firms, which are now pursuing the global development of their candidates as they look to leverage innovation to expand internationally.